BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:507@biocityturku.fi
DTSTART;TZID=Europe/Helsinki:20180904T150000
DTEND;TZID=Europe/Helsinki:20180904T160000
DTSTAMP:20231013T063632Z
URL:https://biocityturku.fi/events/cancer-seminar-series-pharmacology-dire
 cted-strategies-in-anticancer-drug-development-a-viable-approach-for-acade
 mia/
SUMMARY:Cancer Seminar Series: Pharmacology directed strategies in anticanc
 er drug development\, a viable approach for academia?
DESCRIPTION:Dr. Hans Hendriks\, Hendriks Pharmaceutical Consulting\n\nCoffe
 e served at 14:45\n\n&nbsp\;\n\nHans Hendriks\, Ph.D.\, held positions in 
 Cell Biology and Immunology at the Vrije Universiteit (Amsterdam\, The Net
 herlands). After 17 years he joined the New Drug Development Office (now p
 art of INC Research)\, Europe's foremost oncology Contract Research Organi
 sation (Amsterdam\, The Netherlands)\, gaining 12 years experience leading
  international drug discovery and development collaborations. In addition\
 , he served in various drug development and drug evaluation committees of 
 the EORTC\, Cancer Research UK and US National Cancer Institute\, and held
  for 8 years a position in the Executive Board of the EORTC Biological The
 rapeutics Development Group.\n\nHe established Hendriks Pharmaceutical Con
 sulting January 2000\, an independent consultancy company providing servic
 es to small companies and biotechs in Oncology R&amp\;D. He is co-founder 
 of the Biotherapy Development Association (Germany\, 2001) and served on t
 he Scientific Advisory Board of a German biotech company (2001-2003). He w
 as the National Network Representative for The Netherlands in the Council 
 of the European Association for Cancer Research (EACR)\, period 2013-2018\
 , and received a  honorary EACR membership as of 2018.\n\nFrom 2002-2006 
 Dr. Hendriks acted as Project Technical Assistant to the European Commissi
 on (DG Research) in the 5th Framework Programme (FP) overseeing 20 cancer-
 related EU-funded projects\, served as expert evaluator in 5th\, 6th\, 7th
  FP and H2020 of the EU and acted as Administrative Manager for the FP6 Co
 mpuVac project (June 2008-October 2009). In addition\, he assisted Austria
 n\, Dutch\, Italian\, and Slovenian consortia in the preparation and submi
 ssion of grant applications for the European Union's 7th FP\, H2020 and th
 e Innovative Medicines Initiative 2.\n\nHe was successful in bringing the 
 telomere targeting agent KML001 from early stage preclinical research to P
 hase I clinical studies (CCR 2008\;14:4593-602) and is co-inventor of a US
  patent application (2009).\n\nHendriks Pharmaceutical Consulting is membe
 r of the Competence Network Life Science (www.conelis.org)\, an associatio
 n of selected life science experts that provides top-tier consulting servi
 ces to the pharmaceutical industry. It is a network of highly qualified an
 d independent experts who can be contracted individually or as part of an 
 interdisciplinary team.\n\nSelected publications\n\nHendriks. H. et al.\, 
 Pharmacologically directed strategies in academic anticancer drug discover
 y based on the European NCI compounds initiative\, British Journal of Canc
 er\, 2017.\n\nPeters\, GJ.\, Govaerts\, A-S.\, Hendriks\, H. for the EORTC
 -pharmacology and molecular mechanism group. The role of pharmacology in a
 nticancer drug development\, ADMET\, 2018
CATEGORIES:BiocityTurku events,Other events
LOCATION:#_LOCATIONNAME\, #_LOCATIONFULLLINE\, #_LOCATIONCOUNTRY
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=#_LOCATIONFULLLINE\, #_LOCA
 TIONCOUNTRY;X-APPLE-RADIUS=100;X-TITLE=#_LOCATIONNAME:geo:0,0
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
X-LIC-LOCATION:Europe/Helsinki
BEGIN:DAYLIGHT
DTSTART:20180325T040000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR